StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis YoY Growth in the U.S. by Quarter

YoY Growth in the U.S. (% USD / cc) (%)

QuarterlyAnnual

Novartis YoY Growth in the U.S.: 52.0% in Q3 2026.

Latest, Q3 2026
52.0%
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below

Where the Q3 2026 figure comes from

“|| Fabhalta 4 | Oncology | Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G) | 143 | 52 | 94 | 71 | 71 | 237 | 59 | 60”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedYoY Growth in the U.S. (% USD / cc) (%)Year on yearSource
Q3 2026Sep 30, 202652.0%–Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202663.0%–Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202690.0%–Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025157.0%–Novartis Form 6-K (0001114448-26-000007) ↗

Cite this data

StockData. (2026). Novartis YoY Growth in the U.S. (%), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-fabhalta-us-yoy-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.